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The intensive development of molecular biology and biochemistry in recent years has allowed the disclo-
sure of intimate mechanisms of a number of processes in the cell. Numerous molecules have become useful 
tools for diagnosing and predicting a number of diseases. These are, for example, the small, non-coding mi-
cro RNAs (miRNAs). It was found that the majority of protein-coding genes contain miRNA-binding sites un-
der selective pressure (1) that make them the master regulators of cellular processes. Thus, the misexpression 
of miRNAs is associated with many pathological processes, including all cancers, as well as metabolic, cardio-
vascular, neuronal and immune-related diseases (2). In addition, miRNAs could be excreted outside cells from 
which they were transcribed. In humans, extracellular RNAs (exRNAs) have been discovered in bodily fluids, 
such as venous blood, saliva, breast milk, urine, semen, nasal secretion, and vaginal fluid (3). Playing a role in 
intercellular communication and cell regulation, they are a rich source of information about cellular processes 
in both health and disease. Numerous data have shown that exRNAs may serve as diagnostic and prognostic 
biomarkers of cancer (4), cardiovascular (5) and neurodegenerative diseases (6). 
Since the expression patterns of small RNAs have a potential as diagnostic, prognostic, and treatment 
response biomarkers, their intact extraction is essential. Current RNA testing involves isolation of RNA 
usually from patient’s blood samples via standard venipuncture or extraction from formalin-fixed, paraffin-
embedded (FFPE) tissue samples, and then detecting RNA expression patterns in real time using polymerase 
chain reaction (PCR). The clinical importance of FFPE samples consists of retrospective analysis of archival 
tissue that enables the correlation of molecular findings with the response to treatment and the clinical 
outcome. However, the isolation of quality RNA from FFPE specimens is quite complicated, because the 
fixation process causes cross-linkage between nucleic acids and proteins, and covalently modifies RNA by the 
addition of monomethyl groups to the bases. As a result, the molecules are rigid and susceptible to mechanical 
shearing, and the cross-links may compromise the use of RNA as a substrate for reverse transcription (7). In 
order to maintain the integrity of the DNA during the isolation procedure other methods such as proteinase K 
lysis or precipitation with phenol-based reagents are used. Nowadays, most scientists use commercial nucleic 
acid extraction kits based on spin column technology. Spin columns contain a silica resin that selectively binds 
DNA or RNA, depending on salt conditions and other factors influenced by the extraction method. The result 
is high quality material for cloning, long range sequencing and long read sequencing, to name a few potential 
applications. 
Data on comparative analysis of the various methods for isolating intact RNA are much needed to assess 
their advantages and disadvantages and apply the most appropriate method in order to use the microRNAs for 
reliable prediction, early detection and therapeutic response of disease states. Therefore, articles such as that of 
Dimaras et al. that discuss the efficacy of RNA purification and recovery by applying traditional and modern 
methods are timely and useful and give new guidance in methodological work.
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